Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (1021)	2/5/1998 4:01:00 PM
From: Pancho Villa	Read Replies (2) \| Respond to of 1359

Kurt, I generally do not post on threads unless I have a position. Since I didn't before I will explain the reason for my covering. The main reason for covering is that I do not see much short term [i.e., 3-6 months] downside potential and I have limited capital to tie down in short positions [AHP, for example, provides now a better short opportunity]. Just IPIC's intercardia holding is worth over $2/share. IMO, long term, the Redux issue still has the potential of having a significant effect on this small company, lawyer fees, out of court settlements, even if not much damage is done [still to be seen in court] the costs will add up. raising capital will also be an important issue given their high burn rate. As for Citicoline, IMO there is a fair chance that the FDA will not give 100% green light to this drug. The numbers for the original experiment did not show statistically significance for the whole group, so at best I would expect some kind of limited conditional approval, particularly considering the FDA has already shot itself in the foot when approving Redux [many irregularities have been reported in the approval process of Redux. The big reason for being of this company was Redux (ask anyone involved with the company) with Redux gone, life will never be the same again. I wish them good luck with coming up with another clever idea of how to use an existing drug (the only thing they seem to know be capable of doing). Plenty of larger companies with much better resourses are already doing this. I find IPIC's capacity for "adding value" very limited. I hope the reasons above make it clear why IPIC is no longer neither an attractive short/long for me. Regards, Pancho PS: Let's save this post for a couple of years and then see what the outcome was. Of course, I am talking a lot no longer putting my money behind my words, but in this regard apparently I am not the only one.